Evidence map›Paper›PMID 40177173›Full record

ArticleBMJ oncology2025

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation.

Joanna Dodkins, Adrian Cook, Emily Mayne, Marina Parry, Julie Nossiter, Heather Payne, Thomas E Cowling, Alison Tree, Ajay Aggarwal, Noel Clarke and 1 more

Abstract read
In one paragraph

Article in BMJ oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joanna DodkinsDepartment of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0001-7470-3014
Adrian CookNational Cancer Audit Collaborating Centre, Royal College of Surgeons of England, London, UK.
Emily MayneNational Cancer Audit Collaborating Centre, Royal College of Surgeons of England, London, UK.
Marina ParryNational Cancer Audit Collaborating Centre, Royal College of Surgeons of England, London, UK.
Julie NossiterDepartment of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
Heather PayneThe Prostate Centre, London, UK.
Thomas E CowlingDepartment of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
Alison TreeThe Royal Marsden NHS Foundation Trust, London, UK.
Ajay AggarwalDepartment of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0001-9645-6659
Noel ClarkeThe Christie NHS Foundation Trust, Manchester, UK.
Jan van der MeulenDepartment of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the area-based incidence of metastatic prostate cancer at diagnosis, reflecting the risk of late-stage diagnosis, and overall prostate cancer incidence, reflecting the risk of over-diagnosis, in a country without a formal screening programme. Methods and analysis: National study of annual prostate cancer incidence between 2015 and 2019. Mixed-effects regression estimated area-based incidence, adjusted for age, ethnicity and socioeconomic deprivation. Linear regression assessed the association between metastatic and overall cancer incidence. Results: National annual incidence of metastatic prostate cancer was 5.7 per 10 000 men and overall incidence was 43.9. Higher incidence of both metastatic and overall cancer were observed in areas with older populations and with more men with black ethnicity (both p<0.0001). Greater socioeconomic deprivation was linked to higher metastatic but lower overall cancer incidence (p<0.0001). Metastatic incidence varied across the country from 4.0 to 6.8, and prostate cancer overall from 37.9 to 50.1 per 10 000 men. Areas with higher metastatic cancer incidence had lower overall cancer incidence (p<0.0001). Conclusions: There is significant geographic variation in metastatic prostate cancer incidence at diagnosis, with a higher incidence of metastatic cancer observed in areas with a lower overall prostate cancer incidence and in more socioeconomically deprived neighbourhoods, which likely contributes to poorer long-term outcomes. The findings highlight the need for a targeted, risk-based diagnostic approach as well as improved diagnostic facilities and referral pathways. Further research is needed to understand the factors driving this variation in order to reduce metastatic presentations and tackle inequalities in prostate cancer outcomes.

Indexed as

Health Services ResearchMetastatic cancerProstate cancer

Identifiers

PMID40177173
PMCPMC11962787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.